Galunisertib

DB11911InvestigationalSmall molecule

Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.

Mechanism: Pharmacologically active on TGF-beta receptor type-1
Curator reviewed
Formula / weight: C₂₂H₁₉N₅O · 369.428 g/mol (avg)
Code names: LY-2157299

Resolves to

Compound

UNII3OKH1W5LZECAS700874-72-2ChEMBLCHEMBL2364611ChEBI137064PubChem10090485

Structure

InChIKeyIVRXNBXKWIJUQB-UHFFFAOYSA-NSMILESCC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=C2C=C(C=CC2=NC=C1)C(N)=O

Targets

P36897TGFBR1P01137TGFB1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

22Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Galunisertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account